AbbVie signs patent licensing deal with Mylan over Humira biosimilar
AbbVie has entered patent licence agreements with Mylan for the proposed biosimilar product of its Humira (adalimumab) drug. Adalimumab is…
AbbVie has entered patent licence agreements with Mylan for the proposed biosimilar product of its Humira (adalimumab) drug. Adalimumab is…
Mylan has launched Rivastigmine Transdermal System, a generic version of Novartis' Exelon Patch, for the treatment of patients suffering from…